Insulin Lispro Protamine Recombinant

Summary

Insulin Lispro Protamine Recombinant (CHEMBL1201611) is an approved protein; indicated across 2 conditions including diabetes mellitus and type 2 diabetes mellitus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 2 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201611
Name	Insulin Lispro Protamine Recombinant
Type	Protein
Max phase	4

Also known as: Insulin lispro protamine recombinant, INSULIN LISPRO PROTAMINE RECOMBINANT

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
diabetes mellitus	1	MONDO:0005015	EFO:0000400
type 2 diabetes mellitus	1	MONDO:0005148	MONDO:0005148

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).